摘要
G-蛋白偶联受体17(G-protein-coupled receptor 17,GPR17)原是一种孤儿受体,曾被鉴定为新型尿嘧啶核苷酸/半胱氨酰白三烯受体;2011年国际药理学联合会认为,将GPR17归类于白三烯受体条件尚不成熟。GPR17参与多种病理生理过程,如脑损伤、脊髓损伤、少突胶质细胞发育及成熟,这提示GPR17可能成为相关疾病新的治疗靶点。文中就GPR17的配体和拮抗剂、GPR17和其他受体的相互作用及GPR17在中枢神经系统损伤修复中的作用等研究进展进行综述。
G-protein-coupled receptor 17(GPR17),an originally orphan receptor,was identified as a new uracil nucleotides/cysteinyl leukotriene receptor.However,whether GPR17 is really classified as a leukotriene receptor is a matter deserving further investigation.GPR17 is involved in many physiological and pathological processes including brain injury,spinal cord injury,and oligodendrocyte differentiation.GPR17 may become a new therapeutic target in these diseases.In this article,the research progress on the pharmacology and pathophysiological roles of GPR17 is reviewed.
出处
《浙江大学学报(医学版)》
CAS
CSCD
北大核心
2013年第3期355-359,共5页
Journal of Zhejiang University(Medical Sciences)
基金
国家自然科学基金(81173041
81273491)
浙江省钱江人才计划项目(2010R10055)
中央高校基本科研业务费专项资金(2011QNA7015)资助